Chemomab Therapeutics to Release Financial Results
Chemomab Therapeutics Ltd. (NASDAQ: CMMB) is preparing to announce its financial results for the third quarter of 2024. This announcement will occur on November 14, 2024, at 7:00 AM Eastern Time. As a clinical-stage biotechnology firm, Chemomab focuses on developing groundbreaking therapeutics specifically designed for treating fibro-inflammatory diseases—an area with a significant unmet medical need.
Update on Company Developments
The company's press release will include essential updates regarding its latest business strategies and progress in its clinical trials. Individuals interested in discussing the financial outcomes and future plans are encouraged to reach out to their investor relations team.
Innovations in Therapeutics
Chemomab is unique for its novel approach developed around the soluble protein CCL24, which is integral in promoting both fibrosis and inflammation. Their flagship product, CM-101, is an unprecedented dual-activity monoclonal antibody that targets CCL24. Not only has CM-101 shown promise in preclinical settings, but it has also displayed a favorable safety profile and general tolerance across various patient groups.
Clinical Trial Insights
Chemomab has successfully conducted four clinical trials with CM-101, gathering positive feedback and essential data from participants. Recent results from the Phase 2 SPRING trial have been particularly encouraging regarding primary sclerosing cholangitis (PSC), a rare liver condition. Anticipation is building for two pivotal milestones expected in early 2025, which include receiving feedback from the FDA on the design of a planned Phase 3 registrational trial and data from the ongoing open-label extension of the SPRING trial.
Regulatory Designations and Future Plans
CM-101 has earned coveted regulatory designations, including Orphan Drug and Fast Track designations from both the FDA and EMA for its application in PSC. Additionally, the development program for CM-101 targeting systemic sclerosis is ready to transition into Phase 2, with an open Investigational New Drug (IND) application in the United States.
Engaging with Chemomab’s Vision
Chemomab’s commitment to advancing therapies for debilitating fibro-inflammatory diseases reflects a profound understanding of patient needs in the current healthcare landscape. The company aims to transform therapeutic options available for conditions that currently lack effective treatments.
Contact Information for Stakeholders
For inquiries regarding media and investment, stakeholders can contact Chemomab's consulting Vice President of Investor & Public Relations, Barbara Lindheim, at +1 917-355-9234. Interested parties may reach her via email at barbara.lindheim@chemomab.com. Additionally, for investor relations questions, stakeholders can connect through IR@chemomab.com.
Frequently Asked Questions
When will Chemomab Therapeutics announce its Q3 2024 results?
Chemomab Therapeutics plans to release its third-quarter financial results on November 14, 2024.
What is the primary product developed by Chemomab Therapeutics?
The primary product developed by Chemomab is CM-101, a monoclonal antibody targeting the CCL24 protein.
What are the notable designations received by CM-101?
CM-101 has received FDA and EMA Orphan Drug designations, alongside Fast Track status from the FDA.
How many clinical trials has CM-101 completed?
Chemomab has completed four clinical trials of CM-101, yielding positive results across the board.
Who should potential investors contact for more information?
Potential investors are encouraged to contact Chemomab’s Investor Relations at IR@chemomab.com for detailed information.
